With the growing threat of antimicrobial resistance, continued development of new antimicrobial drugs has never been more important. Funding incentives and differing approaches to AMR are currently driving repopulation of the drug development pipeline, and as methods move away from traditional small molecule antibiotics, this is an exciting time for industry in the antimicrobial arena.

Alternative approaches to preventing antimicrobial resistance, as well as the development of new antibiotics, is an innovative and important area of industry focus. With new work into the microbiome, combination treatments, biologic drugs, vaccines, and many other non-traditional approaches besides, trends are showing diversification and innovation in approaching the challenge of increasing antimicrobial resistance.